Chemo4METPANC Combination Chemokine Inhibitor, Immunotherapy, and Chemotherapy in Pancreatic Adenocarcinoma

The purpose of this study is to determine if combination treatment with cemiplimab, motixafortide, gemcitabine, and nab-paclitaxel is effective in decreasing the size of the tumor(s), if it will prolong life in patients, and if it's safe. The treatment consists of standard chemotherapy (gemcitabine and nab-paclitaxel) which is FDA approved and is standard treatment for patients with pancreatic adenocarcinoma. Participants will receive immunotherapy (cemiplimab) which activates the body's immune system to attack cancer cells. Cemiplimab is FDA approved for treatment of skin cancer but not for p

Trial Details

NCT ID
NCT04543071
Phase
PHASE2
Sponsor
Gulam Manji
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • Motixafortide
  • Cemiplimab
  • Gemcitabine
  • Nab paclitaxel
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597
  • Providence, Rhode Island, United States|41.82399,-71.41283
  • Milwaukee, Wisconsin, United States|43.0389,-87.90647

Key Eligibility Criteria

  • Histological or pathological confirmation of metastatic pancreas adenocarcinoma
  • Cytologic or histologic proof of pancreas adenocarcinoma needs to be verified by the treating institution pathologist, either from the initial diag…
  • Pathologic confirmation of metastatic (stage IV) disease (unresectable) on research pretreatment biopsy is required prior to initiation of therapy.
  • Patients with endocrine or acinar pancreatic carcinoma are not eligible for the study.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →